ZPL 3893787

Drug Profile

ZPL 3893787

Alternative Names: PF-03893787; PF-3893787; ZPL-389; ZPL-3893787; ZPL-3893797

Latest Information Update: 18 Jun 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Pfizer
  • Developer Novartis; Pfizer; Ziarco
  • Class Anti-inflammatories; Antiasthmatics; Antipsoriatics; Pyrimidines; Pyrrolidines; Skin disorder therapies; Small molecules
  • Mechanism of Action Histamine H4 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Atopic dermatitis; Plaque psoriasis
  • Discontinued Asthma

Most Recent Events

  • 07 Jun 2018 Phase-II clinical trials in Atopic dermatitis in Iceland (PO) (EudraCT2017-002176-75)
  • 07 May 2018 Novartis Pharmaceuticals plans a phase I/II trial for Atopic Dermatitis in June 2018 , (NCT03517566)
  • 01 Dec 2016 Ziarco Pharma completes a phase II trial in Plaque psoriasis in United Kingdom, USA, Bulgaria and Poland (NCT02618616)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top